AbstractNew helicase assays that recognise therapeutically important G4‐DNA structures will lead to the discovery of novel molecular entities that bind not only to G4‐tetrads, but also to grooves and loops of G4‐DNA. Such assays can also provide inhibitors of G4‐specific helicases that will shed light on the emerging involvement of helicases in cancer and other diseases linked to defective DNA repair pathways.